Biocon Biologics has secured multiple market access agreements for biosimilar to Stelara
Biocon Biologics Ltd , a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access agreements for Yesintek™, its biosimilar to Stelara®. The market access agreements from numerous plans represent over 100+ million lives in the United States.










